Inoviq Ltd
AASX:IIQ0.13
AUD
+0.00
(-3.70%)
ISIN
AU0000196149
Return %
Stock
S&P 500
1Y
-62.32
14.20
3Y
-77.59
81.12
5Y
-88.13
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Leearne Maree Hinch
- Full Time Employees
- 15
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 23 Normanby Road Notting Hill VIC Australia 3168
- IPO Date
- Apr 18, 1991
- Website
- inoviq.com
- Similar Companies
- Business
- INOVIQ Ltd (ASX:IIQ) is an Australia-based biotechnology company that develops and commercializes diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis, monitoring and treatment of cancer and other diseases. Founded in 2016 and headquartered in Notting Hill, Victoria, Australia, with a US office in Wayne, Pennsylvania, the company operates primarily in the oncology sector targeting research institutions, clinical laboratories, pharmaceutical firms and healthcare providers across Europe, North America and Asia-Pacific; it employs approximately 20 staff including 12 R&D personnel. INOVIQ owns or licenses proprietary technologies including SubB2M, NETs, BARD1 and hTERT, underpinning its multi-product pipeline of research tools such as EXO-NET pan-exosome capture kits (in 1.6mL, 1mL and 0.25mL sizes for high-throughput isolation from biofluids), NEURO-NET brain-derived exosome isolation tool (validated for Parkinson's and Alzheimer's), TEXO-NET tumour-derived exosome capture; diagnostics including the commercialized hTERT immunocytochemistry test (Class I IVD in the US as an adjunct to urine cytology for bladder cancer risk), clinical-stage EXO-OC blood-based ovarian cancer screening test (77% sensitivity at >99.6% specificity across all stages, 100% for Stages I/II using exosomal proteins/miRNAs with AI algorithms), neuCA15-3 breast cancer monitoring test (81% sensitivity/93% specificity via SubB2M-enhanced CA15-3); and preclinical exosome therapeutics such as CAR-NK-exosomes (EEV-001 achieving 88% cell death in triple-negative breast cancer and non-small cell lung cancer cells in vitro). The company distributes EXO-NET globally via partner Promega Corporation, which grew customers to 60 across sectors by mid-2025 and develops EXO-NET/RNA combination products for automated workflows (launch expected Q3 FY2026). Recent developments include a A$9.5 million institutional placement and A$2 million share purchase plan in October 2025 to accelerate EXO-OC commercialization as a laboratory-developed test; expansion of EXO-NET revenue to $253k in FY2025 with Promega; validation and peer-reviewed publication of neuCA15-3 in Breast Cancer Research and Treatment (May 2025); in vivo CAR-exosome studies in triple-negative breast cancer mouse models with Peter MacCallum Cancer Centre (data expected Q4 CY2025); appointments of Mary Harney as Non-Executive Director (October 2024) and Dr. Emma Ball as Chief Commercial Officer (April 2025); establishment of a Medical and Scientific Advisory Board (February 2025) chaired by experts in exosomes, immunotherapy and oncology; provisional patent filing for EXO-OC biomarkers (May 2025); and international PCT application for NEURO-NET (October 2024).